Placebo + Denosumab
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Jun 2, 2010 → Mar 26, 2018
NCT ID
NCT01077154About Placebo + Denosumab
Placebo + Denosumab is a phase 3 stage product being developed by Daiichi Sankyo for Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01077154. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01077154 | Phase 3 | Terminated |
Competing Products
20 competing products in Breast Cancer